Ace Laboratories, Inc., an emerging innovator in translating basic research into the physiology of aging into clinical applications, announces the formation of its Scientific and Clinical Advisory Board. Ace Labs is currently developing a proprietary oral-transmucosal dosage form of resveratrol, the drug which has been discussed in the media as “the red wine molecule”. To augment the development of their lead formulation, AIC-101, the Company has assembled a world-class Scientific and Clinical Advisory Board comprised of leading resveratrol researchers and clinicians including:
Chair, James Smoliga, DVM, Ph.D, Associate Professor, Department of Physical Therapy, Department of Basic Pharmaceutical Sciences, High Point University, High Point, North Carolina
Dr. Joseph Baur, Ph.D, Assistant Professor, Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
Dr. Marina Holz, Ph.D., Professor and the Doris and Ira Kukin Chair in Biology at Yeshiva University and Albert Einstein College of Medicine, New York, New York
Dr. R. Scott Turner, MD, Ph.D., Professor, Director of the Memory Disorders Program, Department of Neurology, Georgetown University, Washington, District Of Columbia
“We are elated to announce the formation of our stellar Scientific and Clinical Advisory Board and look forward to working with them to build an exciting new proprietary pharmaceutical pipeline,” said Chief Executive Officer Chip Jacob.
About Ace Laboratories Seattle
Ace Laboratories is focused on enhancing human health via the application of its proprietary technology to unlock the therapeutic potential of resveratrol. It plans to investigate AIC-101, its lead product candidate, in vascular and inflammatory indications such as Alzheimer’s disease and Mild to Moderate Traumatic Brain Injury/Concussion. Resveratrol is a natural polyphenol found in red wine. It captured public interest in 2006 after a landmark study showed that it improved the health-span of rodents. In the decades since, a number of human clinical trials have demonstrated that resveratrol has potential to be helpful to patients with vascular and Alzheimer’s diseases, amongst other conditions associated with aging. However, the molecule’s large-scale potential has been constrained to date by poor oral bioavailability and dose-limiting gastrointestinal side effects. The Company’s management believes that its proprietary technology may effectively address these limitations.
Ace Labs is led by an experienced team including Chief Executive Officer Chip Jacob, Chief Technology Officer Otis Blanchard, Chairman Daniel Wilds, and Corporate Secretary Jim Johnston. The group brings more than a hundred years of collective drug development experience and has a successful working history together.
